Combination Targeted Therapy with Lenvatinib and Pembrolizumab in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers

By sjmartinez • June 27, 2024

French JD, Haugen BR, Worden FP, Bowles DW, Gianoukakis AG, Konda B, Dadu R, Sherman EJ, McCue S, Foster NR, Nikiforov YE, Farias TDJ, Norman PJ, Wirth LJ. Combination Targeted Therapy with Lenvatinib and Pembrolizumab in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers. Clin Cancer Res. 2024 Jun 26. doi: 10.1158/1078-0432.CCR-23-3417. Epub ahead of print. PMID: 38922338.

Tags: Endocrinology, Harbor UCLA, Publications

Increasing Diversity in the Nutrition, Obesity, and Diabetes Biomedical Workforce: The BRIDGES Consortium

Newton RL Jr, Katzmarzyk PT, Duru OK, Lee A, Irwin A, Mangione CM, Morone NE, Ongeri EM, Shaikh SR, Stanford FC, Stanley TL, Truesdale KP;[...]

Closing the Distance: A Qualitative Study to Identify Equitable Innovations for Rural Thyroid Cancer Treatment

Huston-Paterson HH, Mao YV, Hughes EG, Bobanga I, Wu JX, Yeh MW. Closing the Distance: A Qualitative Study to Identify Equitable Innovations for Rural Thyroid[...]

A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liver

Perry AS, Hadad N, Chatterjee E, Jimenez-Ramos M, Farber-Eger E, Roshani R, Stolze LK, Betti MJ, Zhao S, Huang S, Martens L, Kendall TJ, Thone[...]